Research indicates that targeting the mitochondrial serine catabolic pathway (MSCP) presents a potential therapeutic strategy for metastatic breast cancer. The pathway, driven by overexpressed enzymes like serine hydroxymethyltransferase 2 (SHMT2) and methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), supports cancer cell proliferation and metastasis. Researchers investigated the effects of mitochondrial uncouplers, specifically niclosamide ethanolamine (NEN) and BAM15, using uniformly ¹³C-labeled serine and mouse metastasis models. The study found that these uncouplers reduced glycine and purine nucleotide labeling, indicating decreased MSCP activity and de novo purine synthesis. This resulted in increased oxygen consumption and a shifted NAD⁺:NADH ratio, confirming ETC activation. Treatment downregulated SHMT2, MTHFD2, and MTHFD1L proteins in triple-negative breast cancer cells. mRNA levels of these enzymes were unchanged or elevated, suggesting post-transcriptional regulation. Inhibition of FTO, which is downregulated in breast cancer, restored MSCP enzyme expression. Lowering 2-HG, a product of FTO activity, increased m⁶A levels and MSCP enzyme expression, while alpha-ketoglutarate supplementation had the opposite effect. In mice, NEN significantly reduced breast cancer lung metastasis. The findings suggest that reactivating the ETC with uncouplers can restore FTO activity, reduce m⁶A marks on MSCP transcripts, and ultimately target metabolic vulnerabilities in metastatic breast cancer cells. This research highlights a connection between metabolism, the epitranscriptome, and metastasis.